To amend the Internal Revenue Code of 1986 to establish the generic drugs and biosimilars production credit, and for other purposes.
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
This bill, To amend the Internal Revenue Code of 1986 to establish the generic drugs and biosimilars production credit, and for other purposes., changes federal law or congressional policy affecting health care providers and patients. The main policy domain is Healthcare, Finance, Defense.
Who Benefits and How
health care providers and patients may benefit from new authority, funding, eligibility, regulatory clarity, or reduced risk created by the bill.
Who Bears the Burden and How
federal implementing agencies, health care providers and patients may take on implementation duties, reporting obligations, compliance costs, or oversight responsibilities.
Key Provisions
- Section H901B580E5530485684C9F44851A53BD2: 1. Short title This Act may be cited as the Producing Incentives for Long-term production of Lifesaving Supply of medicine Act or the PILLS Act.
- Section H1C535AD977E04A46A33C7455DAB20D91: 2. Generic drugs and biosimilars production credit Subpart D of part IV of subchapter A of chapter 1 of the Internal Revenue Code of 1986 is amended by adding...
- Section HFBE7C6C05C8D4DC295D7691AFFA4A731: 45BB. Generic drugs and biosimilars production credit For purposes of section 38, the generic drugs and biosimilars production credit for any taxable year is...
- Section HBC31822995DB4C1081610F505364C236: 3. Generic drugs and biosimilars investment credit Subpart E of part IV of subchapter A of chapter 1 of the Internal Revenue Code of 1986 is amended by...
- Section HB7581B261F4C4BDFB1BFF1541D94D5C1: 48F. Generic drugs and biosimilars investment credit For purposes of section 46, the generic drugs and biosimilars investment credit for any taxable year is an...
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
This bill, To amend the Internal Revenue Code of 1986 to establish the generic drugs and biosimilars production credit, and for other purposes., changes federal law or congressional policy affecting health care providers and patients.
Key Policy Areas
Healthcare, Finance, Defense
Primary Purpose
This bill, To amend the Internal Revenue Code of 1986 to establish the generic drugs and biosimilars production credit, and for other purposes., changes federal law or congressional policy affecting health care providers and patients.
Policy Domains
Whole bill
Identified Gains
- health care providers and patients
Identified Costs
- federal implementing agencies
- health care providers and patients
Sponsors
Legislative Progress
IntroducedMr. Cotton introduced the following bill; which was read twice …
Impact analysis is available but no clear stakeholder effects identified. View clause-level analysis →
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "the_secretary"
- → The Secretary identified in the operative section
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology